Vivek
https://en.wikipedia.org/wiki/Vivek_Ramaswamy
At Yale he befriended future U.S. Senator J. D. Vance.[30][24]
Now making sense. Definitely a Trump, Miller, Elon, Kushner plant. Vivek keeps saying "Truth to Power" which Q used several times. Trump can't debate so they have Vivek up there.
https://en.wikipedia.org/wiki/Vivek_Ramaswamy
Roivant Sciences and subsidiaries
Ramaswamy in 2017
In 2014, Ramaswamy founded the biotechnology firm Roivant Sciences; the "Roi" in the company's name refers to return on investment.[36] The company was incorporated in Bermuda, a tax haven, and received almost $100 million in start-up capital from QVT and other investors,[36] including RA Capital Management, Visium Asset Management, and the hedge fund managers D. E. Shaw & Co. and Falcon Edge Capital.[33] Roivant's strategy was to purchase patents from larger pharmaceutical companies for drugs that had not yet been successfully developed, and then bring them to the market.[36] The company created numerous subsidiaries,[37][40] including Dermavant (focused on dermatology), Urovant (focused on urological disease), and China-based Sinovant and Cytovant, focused on the Asian market.[37][41]
In 2015, Ramaswamy raised $360 million for the Roivant subsidiary Axovant Sciences in an attempt to market intepirdine as a drug for Alzheimer's disease.[35][42] In December 2014,[43] Axovant purchased the patent for intepirdine from GlaxoSmithKline (where the drug had failed four previous clinical trials) for $5 million, a small sum in the industry.[36] Ramaswamy appeared on the cover of Forbes in 2015, and said his company would "be the highest return on investment endeavor ever taken up in the pharmaceutical industry."[36][42] Before new clinical trials began, he engineered an initial public offering (IPO) in Axovant.[36] Axovant became a "Wall Street darling" and raised $315 million in its IPO.[43] The company's market value initially soared to almost $3 billion, although at the time it only had eight employees, including Ramaswamy's brother and mother.[36] Ramaswamy took a massive payout after selling a portion of his shares in Roivant to Viking Global Investors.[36] He claimed more than $37 million in capital gains in 2015.[36] Ramaswamy said his company would be the "Berkshire Hathaway of drug development"[6] and touted the drug as a "tremendous" opportunity that "could help millions" of patients, prompting some criticism that he was overpromising.[36]
In September 2017, the company announced that intepirdine had failed in its large clinical trial.[36][44] The company's value plunged; it lost 75% in one day and continued to decline afterward.[36] Shareholders who lost money included various institutional investors, such as the California State Teachers' Retirement System pension fund.[36] Ramaswamy was insulated from much of Axovant's losses because he held his stake through Roivant.[36][43] The company abandoned intepirdine. In 2018, Ramaswamy said he had no regrets about how the company handled the drug;[43] in subsequent years, he said he regretted the outcome but was annoyed by criticism of the company.[36] Axovant attempted to reinvent itself as a gene therapy company,[45] but dissolved in 2023.[36]
In 2017, Roivant partnered with the private equity arm of the Chinese state-owned CITIC Group to form Sinovant.[46][47][48] In 2017, Ramaswamy struck a deal with Masayoshi Son in which SoftBank invested $1.1 billion in Roivant.[36] In 2019, Roivant sold its stake in five subsidiaries (or "vants"), including Enzyvant, to Sumitomo Dainippon Pharma;[36][49] Ramaswamy made $175 million in capital gains from the sale.[36] The deal also gave Sumitomo Dainippon a 10% stake in Roivant.[49][50]
While campaigning for the presidency, Ramaswamy called himself a "scientist" and said, "I developed a number of medicines."[36] His undergraduate degree is in biology, but he was never a scientist; his role in the biotechnology industry was that of a financier and entrepreneur.[36]
In January 2021, Ramaswamy stepped down as CEO of Roivant Sciences and assumed the role of executive chairman.[49][50] In 2021, after he resigned as CEO, Roivant was listed on the Nasdaq via a reverse merger with Montes Archimedes Acquisition Corp, a special purpose acquisition vehicle.[51] In February 2023, Ramaswamy stepped down as chair of Roivant to focus on his presidential campaign.[36][52]
Ramaswamy remains the sixth-largest shareholder of Roivant,[36] retaining a 7.17% stake.[7] Roivant has never been profitable.[51]
He is ridiculous. Nobody understands what he is saying. He is not relatable. All he does is attack. He speaks like a crazy salesman. Stand up there speak your truth in a way that is not so bombastic and sell yourself to the American people without being so pompous. It's another terrible choice on those advising Trump.
There's a way to do it and with his personality it would be hard to get it right. I'm all for calling out bullshit.
Trump is on his way into court.
"Jared Kushner is close friends with Vivek (they dine together at Trump’s golf clubs) and as senior adviser to Trump, Kushner pushed a national coronavirus surveillance system around the same time that Vivek said he was was talking to policymakers about it."
https://threadreaderapp.com/thread/1729913580466626893.html
Kushner’s team seeks national coronavirus surveillance system
https://www.politico.com/news/2020/04/07/kushner-coronavirus-surveillance-174165
04/07/2020 07:55 PM EDT
Updated: 04/08/2020 12:19 AM EDT
White House senior adviser Jared Kushner’s task force has reached out to a range of health technology companies about creating a national coronavirus surveillance system to give the government a near real-time view of where patients are seeking treatment and for what, and whether hospitals can accommodate them, according to four people with knowledge of the discussions.
The proposed national network could help determine which areas of the country can safely relax social-distancing rules and which should remain vigilant. But it would also represent a significant expansion of government use of individual patient data, forcing a new reckoning over privacy limits amid a national crisis.